


Amended Claims (Attorney Docket No. LeA 36 080)

1. (Original) A compound of the formula



in which

R¹ denotes 5- to 10-membered heteroaryl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of oxo, halogen, carbamoyl, cyano, hydroxyl, (C₁-C₆-alkyl)carbonyl, trifluoromethyl, trifluoromethoxy, nitro, C₁-C₆-alkyl, C₁-C₆-alkoxy and -NR⁵R⁶,

where

R⁵ and R⁶ independently of one another denote for C₁-C₆-alkyl or

R⁵ and R⁶, together with the nitrogen atom to which they are bonded, denote a 5 to 8-membered heterocycle, which is optionally substituted by C₁-C₆-alkyl or C₁-C₆-hydroxyalkyl,

R² denotes C₁-C₆-alkyl or C₃-C₄-cycloalkyl,

R³ denotes methyl,

A denotes oxygen or NH,

and

R⁴ denotes C₆-C₁₀-aryl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of halogen, formyl, carboxyl, carbamoyl, cyano, hydroxyl, trifluoro-methyl, trifluoromethoxy, nitro, C₁-C₆-alkyl, C₁-C₆-alkoxy, 1,3-dioxa-propane-1,3-diyl, C₁-C₆-alkylthio and -NR⁷R⁸,

in which

R⁷ and R⁸ independently of one another denote hydrogen, C₁-C₆-alkyl or C₁-C₆-alkylcarbonyl,

and their salts, solvates and/or solvates of the salts.

2. (Original) A compound as claimed in claim 1, where

R¹ denotes 5- to 10-membered heteroaryl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of oxo, C₁-C₆-alkyl, C₁-C₆-alkoxy and -NR⁵R⁶,

where

R⁵ and R⁶ independently of one another denote C₁-C₆-alkyl or

R⁵ and R⁶, together with the nitrogen atom to which they are bonded, form a 5 to 8-membered heterocycle, which is optionally substituted by C₁-C₆-alkyl or C₁-C₆-hydroxyalkyl,

R² denotes C₁-C₆-alkyl,

R³ denotes methyl,

A denotes oxygen or NH,

and

R⁴ denotes phenyl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of halogen, C₁-C₆-alkyl and C₁-C₆-alkoxy,

and their salts, solvates and/or solvates of the salts.

3. (Original) A compound as claimed in claim 1 and 2, where

R¹ denotes thienyl, furyl, thiazolyl or pyridyl, which in each case can be substituted by up to 2 substituents selected independently of one another from the group consisting of oxo, C₁-C₆-alkyl, C₁-C₆-alkoxy and -NR⁵R⁶,

where

R⁵ and R⁶ independently of one another denote C₁-C₆-alkyl or

R^5 and R^6 , together with the nitrogen atom to which they are bonded, form a 5 to 8-membered heterocycle, which is optionally substituted by C_1 - C_6 -alkyl or C_1 - C_6 -hydroxyalkyl,


R^2 denotes C_1 - C_6 -alkyl,

R^3 denotes methyl,

A denotes oxygen or NH,

R^4 denotes phenyl, which is substituted by up to 3 C_1 - C_6 -alkoxy radicals,
and their salts, solvates and/or solvates of the salts.


4. (Original) A process for the preparation of compounds as claimed in claim 1, characterized in that compounds of the general formula



in which

R^1 , R^2 and R^3 have the meanings indicated in claim 1,

are reacted with compounds of the formula



in which

R^4 and A have the meanings indicated in claim 1,

to give compounds of the formula (I) and these are optionally reacted with the appropriate (i) solvents and/or (ii) bases or acids to give their solvates, salts and/or solvates of the salts.

5. (Cancelled).
6. (Currently amended) A medicament containing at least one of the compounds as claimed in ~~one of claims claim 1 to 3~~ and at least one pharmaceutically tolerable, essentially nontoxic vehicle or excipient.
7. (Currently amended) ~~The use of the compounds as claimed in one of claims 1 to 3 for the production of a medicament A method~~ for the treatment and/or prophylaxis of neurodegenerative disorders comprising administering to a human or animal an effective amount of a compound of claim 1 or a medicament of claim 6.
8. (Currently amended) ~~The use of the compounds as claimed in one of claims 1 to 3 for the production of a medicament A method~~ for the treatment and/or prophylaxis of cancer, neurodegenerative disorders ~~and or~~ psychiatric disorders comprising administering to a human or animal an effective amount of a compound of claim 1 or a medicament of claim 6.
9. (Currently amended) The use method as claimed in claim 7, ~~where wherein~~ the neurodegenerative disorder is Parkinson's disease.
10. (Currently amended) The use method as claimed in claim 8, ~~where wherein~~ the psychiatric disorder is schizophrenia.
11. (Currently amended) A process for the control of cancer, neurodegenerative disorders ~~and or~~ psychiatric disorders in a human or animal ~~by administration of an efficacious amount of the compounds from claims 1 to 3 comprising administering to a human or animal an effective amount of a compound of claim 1 or a medicament of claim 6.~~
12. (Currently amended) The process as claimed in claim 11, ~~where wherein~~ the neurodegenerative disorder is Parkinson's disease.
13. (Currently amended) The process as claimed in claim 11, ~~where wherein~~ the psychiatric disorder is schizophrenia.